Nanoparticle vaccine formulations for dengue virus
RSC Pharmaceutics · 2026 · 3 (4) · 935-954
DOI: 10.1039/d6pm00015k ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Connor T Murphy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC 4012 Marsico Hall 125 Mason Farm Road Chapel Hill NC 2759…. Die Arbeit nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Dengue virus (DENV) is one of the most prevalent mosquito-borne pathogens, with almost half of the global population at risk of infection.
Autor:innen und Institutionen
- Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC 4012 Marsico Hall 125 Mason Farm Road Chapel Hill NC 27599 USA ainsliek@email.unc.edu.
- Department of Biomedical Engineering, NC State/UNC Chapel Hill NC USA.
- Department of Microbiology and Immunology, School of Medicine, UNC Chapel Hill NC USA.
ORCID-Profile: Kristy M Ainslie
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Murphy, C. T., & Ainslie, K. M. (2026). Nanoparticle vaccine formulations for dengue virus. RSC Pharmaceutics, 3(4), 935-954. https://doi.org/10.1039/d6pm00015k
Vancouver
Murphy CT, Ainslie KM. Nanoparticle vaccine formulations for dengue virus. RSC Pharmaceutics. 2026;3(4):935-954. doi:10.1039/d6pm00015k
BibTeX
@article{Murphy2026,
author = {Murphy, Connor T and Ainslie, Kristy M},
title = {Nanoparticle vaccine formulations for dengue virus},
journal = {RSC Pharmaceutics},
year = {2026},
volume = {3},
number = {4},
pages = {935--954},
doi = {10.1039/d6pm00015k}
}
EUVIMED